DIGITALDX
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Gisela Paulsen
      • Michael Doherty
      • Laura Yecies
      • Laura Mezey
      • Ramin Khaksar
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video
Picture
* Market Opportunity: Breast Cancer > $20B, 20m Mammograms/year in US, 15% result in "call backs"
​* Technology: Non-invasive saliva testing
* Management Team: Life Sciences Veterans. Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics

Market Opportunity: Breast cancer screening is the largest established cancer screening market at over $20B with over 40m mammograms performed annually in the US. But mammography can be uncomfortable, embarrassing, and subject to ambiguous results. For annual screening mammograms, 15% result in “call backs” from ambiguous and inconclusive images. This leaves patients with expensive and invasive workups to obtain more definitive diagnosis including ultrasounds, MRI and surgical biopsy.

Technology: The company has developed a breast cancer screening platform using non-invasive saliva sampling and gene expression profiles to be used as a complement for call backs. Their test is performed as a secondary screen upon a call back on an ambiguous screening mammogram.

Management Team: The company is led by successful life sciences industry veterans with extensive experience building multi-million dollar molecular diagnostics and DNA/RNA technology companies, including Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics. The board is comprised of visionary diagnostics investors (who've returned over $2B in capital to investors) and world leading experts in commercialization of genomics technologies. The scientific advisory board includes academic thought leaders at Stanford, UCSF, UCSC, Tufts and the Univ. of Virginia.
​

Given the elegance of sample collection, simple assay, results to date and experience of the management team, the company is poised to develop a capitally-efficient, results-driven business capable of fundamentally improving breast cancer screening programs. Further, this approach will be of broad interest to the industry, offering strategic partnership and M&A opportunities. 

Michele Colucci is Chairman of the Board
Disclaimer
Terms & Conditions
Privacy Policy
Investment Inquiries
Contact
Picture
Picture
Picture
 Copyright © 2022 All Rights Reserved
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Gisela Paulsen
      • Michael Doherty
      • Laura Yecies
      • Laura Mezey
      • Ramin Khaksar
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video